Aoxing Pharmaceutical Company Inc.
AXN
AXN was delisted on the 16th of October, 2017.
10 hedge funds and large institutions have $3.53M invested in Aoxing Pharmaceutical Company Inc. in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
902% more capital invested
Capital invested by funds: $352K → $3.53M (+$3.17M)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
67% more funds holding
Funds holding: 6 → 10 (+4)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.36M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$125K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$24.7K |
| 4 |
Citigroup
New York
|
+$1.27K |
| 5 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$1.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$80K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$4.29K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $3.16M | +$3.36M | +2,134,054 | New |
|
|
BFA
2
BlackRock Fund Advisors
San Francisco,
California
| $153K | -$4.29K | -2,724 | -3% |
|
|
VKH
3
Virtu KCG Holdings
New York
| $117K | +$125K | +79,060 | New |
|
|
RCM
4
Rotella Capital Management
Bellevue,
Washington
| $46K | +$1.08K | +687 | +2% |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $23K | +$24.7K | +15,700 | New |
|
|
EWM
6
Evercore Wealth Management
New York
| $19K | – | – | – |
|
|
BIM
7
BlackRock Investment Management
Wilmington,
Delaware
| $9K | – | – | – |
|
|
8
Citigroup
New York
| $1K | +$1.27K | +807 | New |
|
|
CK
9
Carnick & Kubik
Colorado Springs,
Colorado
| $222 | +$236 | +150 | New |
|
|
10
AQR Capital Management
Greenwich,
Connecticut
| – | -$80K | -45,700 | Closed |
|
AXN Hedge Fund Activity: Q3 2015 in Review
10 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical Company Inc. (AXN) for Q3 2015, worth a combined $3.53M — up 902% from $352K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AXN positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $3.36M. The largest seller was AQR Capital Management, exiting entirely with an estimated $80K sold.
- 10 institutional investors held Aoxing Pharmaceutical Company Inc. (AXN) as of Q3 2015, up from 6 in Q2 2015.
- Funds reported $3.53M of Aoxing Pharmaceutical Company Inc. stock for Q3 2015, up 902% quarter-over-quarter.
- 5 funds opened new Aoxing Pharmaceutical Company Inc. positions in Q3 2015 and 1 closed out, a net change of +4 holders.
- The largest Aoxing Pharmaceutical Company Inc. buyer in Q3 2015 was Sabby Management, an estimated $3.36M added.
- The largest Aoxing Pharmaceutical Company Inc. seller in Q3 2015 was AQR Capital Management, an estimated $80K sold.
Based on aggregated 13F filings for Q3 2015.